Conflict of interest statement: None.191. ESMO Open. 2018 Mar 29;3(3):e000350. doi: 10.1136/esmoopen-2018-000350.eCollection 2018.Controversies in oncology: which adjuvant endocrine therapy is to be given topremenopausal patients with hormone receptor-positive breast cancer?Lambertini M(1)(2), Viglietti G(2), de Azambuja E(1).Author information: (1)Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles(ULB), Brussels, Belgium.(2)Breast Cancer Translational Research Laboratory, Institut Jules Bordet,Université Libre de Bruxelles (ULB), Brussels, Belgium.DOI: 10.1136/esmoopen-2018-000350 PMCID: PMC5890055PMID: 29636992 